BackInhibikase Therapeutics Overview

Inhibikase Therapeutics Current Cash

Inhibikase Therapeutics's current cash is $50M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$49.57M
↓ 32.50% YoYΔ $-23.87M vs prior year quarter

Peer average

Loading

Inhibikase Therapeutics Current Cash History

Loading

Inhibikase Therapeutics vs. peers: Current Cash Comparison

Loading

Inhibikase Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Inhibikase Therapeutics (IKT) FAQ

As of the most recent data (March 2026), IKT shows a current cash of $50M. That compares with $73M in the prior-year period — down 32.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, IKT's current cash is now $50M (was $73M) — a 32.5% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Inhibikase Therapeutics is outperforming or lagging.

Tracking IKT's current cash over time shows whether Inhibikase Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $50M That compares with $73M in the prior-year period — down 32.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Inhibikase Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $50M) with ownership activity and broader fundamentals.

Inhibikase Therapeutics's current cash is $50M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.